Pharmaceutical

Aquestive Therapeutics to Participate in The Citizens JMP Life Sciences Conference

WARREN, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to bring…

5 months ago

ORYZON to Provide Corporate Progress Updates at Several Events in May

Bio-Equity Europe 2024Asebio Investor Day 2024RSC Hot Topics: Covalent Drug DiscoveryForo Medcap BME 2024 MADRID, Spain and CAMBRIDGE, Mass., May…

5 months ago

Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension

- FDA indicated IkT-001Pro can be considered a New Molecular Entity and is eligible for exclusivity designations in Pulmonary Arterial…

5 months ago

Annexon Biosciences to Present at the Bank of America Health Care Conference

BRISBANE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform…

5 months ago

IRLAB Enters a Development Collaboration for IRL757 as a Novel Treatment for Apathy

ANNOUNCEMENT FOR EUROPEAN MEDICAL & PHARMACEUTICAL TRADE MEDIA AND EUROPEAN FINANCIAL MEDIA ONLYGOTHENBURG, SE / ACCESSWIRE / May 7, 2024…

5 months ago

Outcome Capital Continues to Expand with the Addition of Industry Veteran Stanislav Glezer, MD MBA

Dr. Glezer’s appointment as Managing Director will strengthen Outcome’s healthcare innovation and product launch expertiseBOSTON--(BUSINESS WIRE)--Outcome Capital, LLC, a highly…

5 months ago

TriSalus Life Sciences Appoints Liselotte Hyveled to its Board of Directors

– Accomplished industry veteran brings deep strategic and operational expertiseDENVER--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (Nasdaq: TLSI), an oncology company integrating…

5 months ago

FSD Pharma Submits a Phase-1 Multiple Ascending Doses Clinical Trial Application for Lucid-21-302 (Lucid-MS) for Ethics Committee Review in Australia

TORONTO, ON / ACCESSWIRE / May 7, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical…

5 months ago

Ipsen S.A. – Formalities for making available and consulting preparatory documents to the 2024 Annual General Meeting

    Information relating to the holding of the Combined Shareholders’ Meeting of 28 May 2024 of Ipsen S.A. Formalities…

5 months ago

Inozyme Pharma Reports First Quarter 2024 Financial Results and Provides Business Highlights

- Interim data from SEAPORT-1, a Phase 1 trial of INZ-701 in patients with end-stage kidney disease receiving hemodialysis, on…

5 months ago